Pfizer and BioNTech Enter into Agreement with COVAX for COVID-19 Vaccine Delivery

January 25, 2021
BioPharm International Editors

The companies have entered into an advance purchase agreement with COVAX to provide up to 40 million doses of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, to lower-middle-income countries.

Pfizer and BioNTech announced on Jan. 22, 2021 that they have entered into an advance purchase agreement with COVAX, a global initiative focused on providing lower-middle-income countries with access to COVID-19 vaccines, for up to 40 million doses of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2.

Under the terms of the agreement, the first doses of the vaccine will be delivered during the first quarter of 2021 and will be provided to COVAX at a not-for-profit, undisclosed price, Pfizer said in a company press release.

"At Pfizer, we believe that every person deserves to be seen, heard, and cared for. That's why from the very beginning of our vaccine development program, Pfizer and BioNTech have been firmly committed to working toward equitable and affordable access of COVID-19 vaccines for people around the world," said Pfizer Chairman and CEO Albert Bourla, in the press release. "We share the mission of COVAX and are proud to work together so that developing countries have the same access as the rest of the world, which will bring us another step closer to ending this global pandemic and proving that science will win for everyone, everywhere."

“SARS-CoV-2 does not differentiate between borders—a global pandemic requires comprehensive solutions and worldwide collaboration. COVAX is a truly global initiative and we are happy to support by making BNT162b2 available in many low- and lower-middle-income countries to help protect vulnerable people worldwide,” added Ugur Sahin, MD, CEO and co-founder of BioNTech, in the press release.

Source: Pfizer